→ Just weeks af­ter post­ing promis­ing piv­otal re­sults for re­l­u­golix in prostate can­cer, My­ovant has picked up a pri­or­i­ty re­view from the FDA, which isn’t plan­ning an ex­pert com­mit­tee re­view be­fore mak­ing its de­ci­sion. While much of the at­ten­tion in this class is fo­cused on uter­ine fi­broids, an OK here would make this the first GnRH re­cep­tor an­tag­o­nist treat­ment for men with ad­vanced prostate can­cer.

A cou­ple of new Chi­na deals ar­rived in to­day’s news feed. Agenus struck an agree­ment with Bet­ta Phar­ma­ceu­ti­cals for an ex­clu­sive col­lab­o­ra­tion and li­cense agree­ment for the de­vel­op­ment and com­mer­cial­iza­tion of bal­stil­imab and za­l­ifre­limab in Greater Chi­na. Agenus will re­ceive $35 mil­lion, which in­cludes $15 mil­lion in up­front cash and a $20 mil­lion eq­ui­ty in­vest­ment. The agree­ment al­so in­cludes $100 mil­lion in po­ten­tial mile­stones plus roy­al­ties on net sales. Al­so, G1 Ther­a­peu­tics and Genor Bio­phar­ma an­nounced an ex­clu­sive li­cense agree­ment for the de­vel­op­ment and com­mer­cial­iza­tion of le­ro­ci­clib in the Asia-Pa­cif­ic re­gion (ex­clud­ing Japan). G1 will re­ceive an up­front cash pay­ment of $6 mil­lion and be el­i­gi­ble to re­ceive up to an ad­di­tion­al $40 mil­lion in de­vel­op­ment and com­mer­cial mile­stone pay­ments.

→ Shang­hai’s STAR board has wel­comed its largest biotech, as Sinocell­Tech lands on the sci­ence and tech­nol­o­gy-fo­cused board with a $181 mil­lion raise in hand and sport­ing a $5 bil­lion mar­ket cap. Qim­ing Ven­ture Part­ners led its Se­ries A back in 2017, and many of its ex­per­i­men­tal prod­ucts — span­ning mon­o­clon­al an­ti­bod­ies, re­com­bi­nant pro­teins and vac­cines — have now en­tered Phase III.

Source link